Indonesia’s BPOM Grants IND Approval For SCI To Conduct A Phase 2 Clinical Trial Using Stemedica Cell Technologies, Inc.’s Mesenchymal Stem Cells To Treat Acute Myocardial Infarction

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SAN DIEGO--(BUSINESS WIRE)--Stemedica Cell Technologies Inc., a leading manufacturer of adult, allogeneic stem cells and stem cell factors, announces that its research partner The Stem Cell and Cancer Institute (SCI), a subsidiary of PT Kalbe Farma Tbk, Indonesia, received an IND approval in April 2014 from the Badan Pengawas Obat dan Makanan (BPOM, or the Indonesian FDA) for a Phase II study using Stemedica’s mesenchymal stem cells to treat acute myocardial infarction (AMI) in human subjects in Indonesia. The IND was filed by SCI with support from Stemedica Asia, a subsidiary of Stemedica, and was based on Stemedica’s United States FDA-approved Phase II AMI trial protocol.

Help employers find you! Check out all the jobs and post your resume.

Back to news